



**SASKATCHEWAN FORMULARY COMMITTEE  
BULLETIN  
54th Edition**

**NEW FULL FORMULARY  
LISTING**

*The following product will be listed effective July 1, 2004.*

- Trandolapril, capsule, 0.5mg, 4mg (Mavik-ABB)
- Mirtazapine, tablet, 15mg (RhoXal-Mirtazapine-RHO)

**NEW EXCEPTION DRUG  
STATUS AGENTS**

*Effective July 1, 2004 the following products will be available under Exception Drug Status subject to the indicated criteria.*

- **Brimonidine tartrate, ophthalmic solution, 0.15% (Alphagan P-ALL)**  
For patients intolerant to benzalkonium chloride.
- **Tiotropium bromide monohydrate, inhalation powder capsule, 18ug/dose (Spiriva-BOE)**  
For the treatment of patients with COPD not responding to short-acting beta agonists or short-acting anticholinergic bronchodilators.

**NOTE:** EDS has been approved for the following two new proton pump inhibitors according to the same EDS criteria as published in Appendix A of the Saskatchewan Formulary. These two products will come under the new MAC policy effective July 1, 2004.

- **Esomeprazole magnesium trihydrate, delayed release**

**tablet, 20mg, 40mg (Nexium-AST)**

Same EDS criteria as currently listed proton pump inhibitors published in Appendix A of the Saskatchewan Formulary.

- **Omeprazole, capsule, 20mg (Apo-Omeprazole-APX)**  
Same EDS criteria as currently listed proton pump inhibitors published in Appendix A of the Saskatchewan Formulary.

*Note: There is insufficient evidence to determine the interchangeability of this product with Losec tablets-AST at this time. For patients to receive the Apo product, the physician must write "Apo-Omeprazole" on the prescription.*

**CHANGE IN STATUS FROM EDS  
TO FULL FORMULARY**

- Etidronate disodium, tablet, 200mg (Didronel-PGA)
- Etidronate disodium, tablet, 200mg (Gen-Etidronate-GPM)

**NEW FULL FORMULARY  
INTERCHANGEABLE LISTINGS**

*The following products will be listed as interchangeable effective July 1, 2004.*

- Amitriptyline, tablet, 10mg, 25mg, 50mg (Dom-Amitriptyline-DOM)
- Azathioprine, tablet, 50mg (Nu-Azathioprine-NXP)

- Citalopram hydrobromide, tablet, 20mg, 40mg (Dom-Citalopram-DOM)
- Citalopram hydrobromide, tablet, 20mg, 40mg (Novo-Citalopram-NOP)
- Citalopram hydrobromide, tablet, 20mg, 40mg (Nu-Citalopram-NXP)
- Dexamethasone, tablet, 4mg (Apo-Dexamethasone-APX)
- Fenofibrate, capsule, 200mg (Nu-Feno-Micro-NXP)
- Fosinopril, tablet, 10mg, 20mg (Lin-Fosinopril-LIN)
- Framycetin SO<sub>4</sub>/Gramicidin/Dexamethasone Base, solution, 5mg/50UG/0.5mg per mL (Sab-Opticort- SAB)
- Furosemide, tablet, 20mg, 40mg (Nu-Furosemide-NXP)
- Gabapentin, capsules, 100mg, 300mg, 400mg (Prem-Gabapentin-PRM)
- Hydrochlorothiazide, tablet, 25mg, 50mg (Dom-Hydrochlorothiazide-DOM)
- Hydrochlorothiazide, tablet, 25mg, 50mg (Nu-Hydro-NXP)
- Mirtazapine, tablet, 30mg (RhoXal-Mirtazapine-RHO)
- Paroxetine HCl, tablet, 10mg, 20mg, 30mg (Nu-Paroxetine-NXP)
- Pravastatin, tablet, 10mg, 20mg, 40mg (Dom-Pravastatin-DOM)
- Propafenone HCL, tablet, 150mg (Nu-Propafenone-NXP)
- Ranitidine, tablet, 150mg, 300mg (CO Ranitidine-COB)
- Simvastatin, 5mg, 10mg, 20mg, 40mg, 80mg (Novo-Simvastatin-NOP)

- Terbinafine HCl, tablet, 250mg (Nu-Terbinafine-NXP)
- Verapamil HCL, sustained release tablet, 240mg (Nu-Verap SR-NXP)

**CHANGE IN STATUS FROM NON-INTERCHANGEABLE TO INTERCHANGEABLE**

- Hydroxychloroquine SO<sub>4</sub>, tablet, 200mg (Apo-Hydroxyquine-APX)

**NEW FULL FORMULARY NON-INTERCHANGEABLE LISTING**

*The following product will be listed as non-interchangeable effective July 1, 2004.*

- Prochlorperazine, suppository, 10mg (Sab-Prochlorperazine-SAB)

**NEW EXCEPTION DRUG STATUS INTERCHANGEABLE AGENTS**

*Effective July 1, 2004 the following interchangeable products will be covered under the same Exception*

*Drug Status criteria as the currently listed dosage forms.*

- Carvedilol, tablet, 3.125mg, 6.25mg, 12.5mg, 25mg (Dom-Carvedilol-DOM)
- Carvedilol, tablet, 3.125mg, 6.25mg, 12.5mg, 25mg (Nu-Carvedilol-NXP)
- Ciprofloxacin, tablet, 250mg, 500mg, 750mg (Dom-Ciprofloxacin-DOM)
- Ciprofloxacin, tablet, 250mg, 500mg, 750mg (Prem-Ciprofloxacin-PRM)
- Meloxicam, tablet, 7.5mg, 15mg (Apo-Meloxicam-APX)
- Meloxicam, tablet, 7.5mg, 15mg (Dom-Meloxicam-DOM)
- Octreotide acetate, injection (vial), 50ug/mL, 100ug/mL, 200ug/mL, 500ug/mL (Octreotide Acetate-OMG)

**SOME OF THE PRODUCTS CURRENTLY UNDER REVIEW BY THE FORMULARY COMMITTEE**

- Almotriptan malate, tablet, 6.25mg, 12.5mg (Axert-JAN)
- Atazanavir SO<sub>4</sub>, capsule, 150mg, 200mg (Reyataz-BMY)

- Brimonidine tartrate/timolol maleate, ophthalmic solution, 0.2%/0.5% (Combigan-ALL)
- Clozapine, tablet, 25mg, 100mg (Gen-Clozapine-GPM)
- Clozapine, tablet, 25mg, 100mg (Apo-Clozapine-APX)
- Cyclosporine, liquid, 100mg/mL (Apo-Cyclosporine-APX)
- Cyclosporine, capsule, 100mg (Rhoal-Cyclosporine-RHO)
- Norelgestromin/ethinyl estradiol, transdermal system, 6.0mg/0.6mg (Evra-JAN)
- Olanzapine, powder for injection (vial), 10mg/vial (Zyprexa IM-LIL)
- Peginterferon alfa-2a, injection (pre-filled syringe), 180ug/0.5mL, (vial) 180ug/1mL (Pegasys-HLR)

**PRODUCTS NOT RECOMMENDED FOR COVERAGE**

- Doxycycline hyclate, capsule, 20mg (Periostat-PMS)  
The clinical benefit does not justify the cost.

**DELISTED PRODUCTS**

**Paroxetine HCl, tablet, 10mg (Dom-Paroxetine-DOM)**

The company has requested this product be delisted from the Formulary effective immediately.

**Hospital Benefit Drug List**

The Hospital Benefit Drug List is now located in the Supplementary Information section of the Formulary.

**ADDITIONS AND DELETIONS BULLETIN**

The summary of Additions and Deletions Bulletin is available on the website at: <http://formulary.drugplan.health.gov.sk.ca>. This document summarizes all products that have been approved as additions to the formulary, and all products that have been deleted since the last edition.

## DRUG PLAN UPDATE

### Update Stickers

In response to feedback from physicians, the Drug Plan will no longer provide printed quarterly update stickers to physicians. From now on the Drug Plan will make the quarterly update stickers available to physicians on an "as requested" basis only. Physicians who choose not to receive update stickers will still receive the quarterly SFC bulletin and the annual Formulary (published in late June each year). Physicians who wish to continue receiving update stickers can fax a request for their name be added to the sticker update mailing list to FAX (306) 787-8679 (Attention: Lorna). Please include complete mailing address with the request.

Update information can also be found on the on-line Formulary which is updated quarterly. The on-line Formulary can be accessed via the internet at <http://formulary.drugplan.health.gov.sk.ca>. The on-line version is easy to use and is "searchable" by drug brand name, generic name and Drug Identification Number (DIN).

Also available on this site is a downloadable PDF version of the Formulary, information regarding the Drug Plan & Extended Benefits Branch programs, Drug Plan Annual Statistical Reports, Formulary Committee bulletins, and program application forms.

### **MAXIMUM ALLOWABLE COST POLICY**

The Drug Plan will be implementing a new policy on July 1, 2004 called the Maximum Allowable Cost (MAC) policy. The MAC policy is being introduced to help ensure sustainability of the Drug Plan into the future.

Implementation of the MAC policy will be phased in, initially starting with one category of drugs (the Proton Pump Inhibitors) and expanding to other drug classes in the future. Mailings to

physicians and pharmacists provide details regarding the MAC policy and how the policy will affect Drug Plan reimbursement of Proton Pump Inhibitors. Information is also available on the Drug Plan website at <http://formulary.drugplan.health.gov.sk.ca>

**Saskatchewan Formulary Committee**  
**2nd Floor, 3475 Albert Street**  
**Regina, Saskatchewan S4S 6X6**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Formulary Committee. Inquiries should be directed to the address shown at left.

**FORMULARY AND EDS UPDATES EFFECTIVE JULY 1, 2004**

<b><u>GENERIC &amp; TRADE</u></b>			<b><u>UNIT</u></b>	
<b><u>NAME</u></b>	<b><u>STRENGTH &amp; FORM</u></b>	<b><u>DIN</u></b>	<b><u>PRICE</u></b>	<b><u>LEGEND</u></b>
<b>Amitriptyline</b>				
Dom-Amitriptyline	10mg tablet	02248131	0.0594	I/C
Dom-Amitriptyline	25mg tablet	02248132	0.1134	I/C
Dom-Amitriptyline	50mg tablet	02248133	0.2109	I/C
<b>Azathioprine</b>				
Nu-Azathioprine	50mg tablet	02248843	0.5879	I/C
<b>Brimonidine tartrate</b>				
Alphagan P (EDS)	0.15% ophthalmic solution	02248151	3.5805	EDS
<b>Carvedilol</b>				
*Dom-Carvedilol (EDS)	3.125mg tablet	02248748	0.7728	I/C EDS
*Dom-Carvedilol (EDS)	6.25mg tablet	02248749	0.7728	I/C EDS
*Dom-Carvedilol (EDS)	12.5mg tablet	02248750	0.7728	I/C EDS
*Dom-Carvedilol (EDS)	25mg tablet	02248751	0.7728	I/C EDS
Nu-Carvedilol (EDS)	3.125mg tablet	02248715	0.9646	I/C EDS
Nu-Carvedilol (EDS)	6.25mg tablet	02248716	0.9646	I/C EDS
Nu-Carvedilol (EDS)	12.5mg tablet	02248717	0.9646	I/C EDS
Nu-Carvedilol (EDS)	25mg tablet	02248718	0.9646	I/C EDS
<b>Ciprofloxacin</b>				
Dom-Ciprofloxacin (EDS)	250mg tablet	02251272	1.7712	I/C EDS
Dom-Ciprofloxacin (EDS)	500mg tablet	02251280	1.9984	I/C EDS
Dom-Ciprofloxacin (EDS)	750mg tablet	02251299	3.7690	I/C EDS
Prem-Ciprofloxacin (EDS)	250mg tablet	02249960	1.6869	I/C EDS
Prem-Ciprofloxacin (EDS)	500mg tablet	02249979	1.9032	I/C EDS
Prem-Ciprofloxacin (EDS)	750mg tablet	02249987	3.5895	I/C EDS
<b>Citalopram</b>				
*Dom-Citalopram	20mg tablet	02248942	0.6661	I/C
*Dom-Citalopram	40mg tablet	02248943	0.6661	I/C
Novo-Citalopram	20mg tablet	02251558	0.9494	I/C
Novo-Citalopram	40mg tablet	02251566	0.9494	I/C
Nu-Citalopram	20mg tablet	02248996	0.9494	I/C
Nu-Citalopram	40mg tablet	02248997	0.9494	I/C
<b>Dexamethasone</b>				
Apo-Dexamethasone	4mg tablet	02250055	0.8329	I/C

<u>GENERIC &amp; TRADE</u> <u>NAME</u>	<u>STRENGTH &amp; FORM</u>	<u>DIN</u>	<u>UNIT</u> <u>PRICE</u>	<u>LEGEND</u>
<b>Esomeprazole Magnesium Trihydrate</b>				
Nexium (EDS)	20mg delayed release tablet	02244521	2.2785	EDS
Nexium (EDS)	40mg delayed release tablet	02244522	2.2785	EDS
<b>Fenofibrate</b>				
Nu-Feno-Micro	200mg capsule	02249715	1.1816	I/C
<b>Fosinopril</b>				
Lin-Fosinopril	10mg tablet	02242733	0.6000	I/C
Lin-Fosinopril	20mg tablet	02242734	0.7216	I/C
<b>Furosemide</b>				
*Nu-Furosemide	20mg tablet	02239224	0.0336	I/C
*Nu-Furosemide	40mg tablet	02239225	0.0503	I/C
<b>Gabapentin</b>				
Prem-Gabapentin	300mg capsule	02249375	0.6651	I/C
Prem-Gabapentin	400mg capsule	02249383	0.7926	I/C
<b>Hydrochlorothiazide</b>				
*Nu-Hydro	25mg tablet	02250659	0.0357	I/C
*Nu-Hydro	50mg tablet	02250667	0.0517	I/C
Dom-Hydrochlorothiazide	25mg tablet	02248134	0.0543	I/C
Dom-Hydrochlorothiazide	50mg tablet	02248135	0.0743	I/C
<b>Meloxicam</b>				
Apo-Meloxicam (EDS)	7.5mg tablet	02248973	0.5925	I/C EDS
Apo-Meloxicam (EDS)	15mg tablet	02248974	0.6836	I/C EDS
Dom-Meloxicam (EDS)	7.5mg tablet	02248605	0.6221	I/C EDS
Dom-Meloxicam (EDS)	15mg tablet	02248606	0.7178	I/C EDS
<b>Mirtazapine</b>				
Rhoxal-Mirtazapine	15mg tablet	02250594	0.4709	
Rhoxal-Mirtazapine	30mg tablet	02250608	0.9418	I/C
<b>Octreotide acetate</b>				
Octreotide acetate (EDS)	50ug/mL injection (1mL)	02248639	4.3300	I/C EDS
Octreotide acetate (EDS)	100ug/mL injection (1mL)	02248640	8.1900	I/C EDS
Octreotide acetate (EDS)	200ug/mL injection (1mL)	02248642	78.6500	I/C EDS
Octreotide acetate (EDS)	500ug/mL injection (1mL)	02248641	38.4400	I/C EDS
<b>Omeprazole</b>				
Apo-Omeprazole (EDS)	20mg capsule	02245058	1.3563	EDS
<b>Paroxetine HCl</b>				
Nu-Paroxetine	10mg tablet	02248719	1.1317	I/C
Nu-Paroxetine	20mg tablet	02248720	1.2076	I/C
Nu-Paroxetine	30mg tablet	02248721	1.2836	I/C

<u>GENERIC &amp; TRADE NAME</u>	<u>STRENGTH &amp; FORM</u>	<u>DIN</u>	<u>UNIT PRICE</u>	<u>LEGEND</u>
<b>Polymyxin B SO4/Bacitracin (Zinc)/Neomycin SO4/Hydrocortisone</b>				
Sab-Cortimyxin	10000u/400u/5mg/10mg/g (3.5g)	02242485	8.9700	I/C
<b>Pravastatin</b>				
Dom-Pravastatin	10mg tablet	02249723	1.0862	I/C
Dom-Pravastatin	20mg tablet	02249731	1.2810	I/C
Dom-Pravastatin	40mg tablet	02249758	1.5429	I/C
<b>Prochlorperazine</b>				
Sab-Prochlorperazine	10mg suppository	00789720	0.9010	Not I/C
<b>Propafenone HCl</b>				
Nu-Propafenone	150mg tablet	02249480	0.4639	I/C
<b>Ranitidine</b>				
CO Ranitidine	150mg capsule	02248570	0.4386	I/C
CO Ranitidine	300mg capsule	02248571	0.8449	I/C
<b>Simvastatin</b>				
Novo-Simvastatin	5mg tablet	02250144	0.6152	I/C
Novo-Simvastatin	10mg tablet	02250152	1.2168	I/C
Novo-Simvastatin	20mg tablet	02250160	1.5039	I/C
Novo-Simvastatin	40mg tablet	02250179	1.5039	I/C
Novo-Simvastatin	80mg tablet	02250187	1.5039	I/C
<b>Terbinafine HCl</b>				
<b>*Nu-Terbinafine</b>	250mg tablet	02248845	2.1943	I/C
<b>Tiotropium Bromide Monohydrate</b>				
Spiriva (EDS)	18ug/dose powder capsule	02246793	2.2785	EDS
<b>Trandolapril</b>				
Mavik	0.5mg capsule	02231457	0.6727	
Mavik	4mg capsule	02239267	1.0308	
<b>Verapamil HCl</b>				
<b>*Nu-Verap SR</b>	240mg sustained release tablet	02249812	0.7211	I/C

---

**LEGEND:** EDS = Exception Drug Status  
I/C = Interchangeable  
Not I/C = Not Interchangeable  
\***Bold Type** = SOC Contract

## **CRITERIA FOR NEW EXCEPTION DRUG STATUS (EDS) ADDITIONS**

### **NEW EXCEPTION DRUG STATUS AGENTS**

*Effective July 1, 2004 the following products will be available for coverage under Exception Drug Status subject to the indicated criteria:*

- **Brimonidine tartrate, ophthalmic solution, 0.15% (Alphagan P-ALL)**  
For patients intolerant to benzalkonium chloride.
- **Esomeprazole magnesium trihydrate, delayed release tablet, 20mg, 40mg (Nexium-AST)**  
Same EDS criteria as currently listed proton pump inhibitors published in Appendix A of the Saskatchewan Formulary.
- **Omeprazole, capsule, 20mg Apo-Omeprazole-APX)**  
Same EDS criteria as currently listed proton pump inhibitors published in Appendix A of the Saskatchewan Formulary.  
*Note: There is insufficient evidence to determine the interchangeability of this product with Losec-AST tablets at this time. For patients to receive the Apo product, the physician must write "Apo-Omeprazole: on the prescription."*
- **Tiotropium bromide monohydrate, inhalation powder capsule, 18ug/dose (Spiriva-BOE)**  
For the treatment of patients with COPD not responding to short-acting beta agonists or short-acting anticholinergic bronchodilators.

### **NEW EXCEPTION DRUG STATUS INTERCHANGEABLE AGENTS**

*Effective July 1, 2004 the following interchangeable products will be covered under the same Exception Drug Status criteria as the currently listed dosage forms.*

- Carvedilol, tablet, 3.125mg, 6.25mg, 12.5mg, 25mg (Dom-Carvedilol-DOM)
- Carvedilol, tablet, 3.125mg, 6.25mg, 12.5mg, 25mg (Nu-Carvedilol-NXP)
- Ciprofloxacin, tablet, 250mg, 500mg, 750mg (Dom-Ciprofloxacin-DOM)
- Ciprofloxacin, tablet, 250mg, 500mg, 750mg (Prem-Ciprofloxacin-PRM)
- Meloxicam, tablet, 7.5mg, 15mg (Apo-Meloxicam-APX)
- Meloxicam, tablet, 7.5mg, 15mg (Dom-Meloxicam-DOM)
- Octreotide acetate, injection (vial), 50ug/mL, 100ug/mL, 200ug/mL, 500ug/mL (Octreotide Acetate-OMG)

### **CHANGE IN STATUS FROM EDS TO FULL FORMULARY**

- Etidronate disodium, tablet, 200mg (Didronel-PGA)
- Etidronate disodium, tablet 200mg (Gen-Etidronate-GPM)

### **CHANGE IN STATUS FROM NOT-INTERCHANGEABLE TO INTERCHANGEABLE**

- Hydroxychloroquine SO<sub>4</sub>, tablet, 200mg (Apo-Hydroxyquine-APX)